"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in Harvard Catalyst Profiles by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 10 | 7 | 17 |
1995 | 14 | 12 | 26 |
1996 | 37 | 23 | 60 |
1997 | 28 | 26 | 54 |
1998 | 39 | 35 | 74 |
1999 | 28 | 34 | 62 |
2000 | 43 | 33 | 76 |
2001 | 39 | 32 | 71 |
2002 | 36 | 36 | 72 |
2003 | 39 | 36 | 75 |
2004 | 49 | 39 | 88 |
2005 | 47 | 43 | 90 |
2006 | 43 | 46 | 89 |
2007 | 49 | 33 | 82 |
2008 | 35 | 45 | 80 |
2009 | 53 | 71 | 124 |
2010 | 56 | 49 | 105 |
2011 | 42 | 51 | 93 |
2012 | 61 | 45 | 106 |
2013 | 56 | 48 | 104 |
2014 | 64 | 45 | 109 |
2015 | 64 | 60 | 124 |
2016 | 45 | 53 | 98 |
2017 | 58 | 54 | 112 |
2018 | 44 | 45 | 89 |
2019 | 49 | 48 | 97 |
2020 | 59 | 42 | 101 |
2021 | 42 | 55 | 97 |
2022 | 5 | 44 | 49 |
2023 | 6 | 39 | 45 |
2024 | 1 | 8 | 9 |
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis. Ann Am Thorac Soc. 2024 Mar; 21(3):474-485.
-
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. Lancet Neurol. 2024 Mar; 23(3):267-276.
-
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial. Ann Rheum Dis. 2024 Feb 15; 83(3):351-359.
-
Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Feb; 21(2):317-327.
-
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177.
-
Immunosuppressant drug monitor: A non-invasive device to measure tacrolimus level in the saliva of transplanted patients. Int J Pharm. 2024 Mar 25; 653:123858.
-
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024 Jan 15; 209(2):137-152.
-
Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan; 21(1):136-150.
-
Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan; 21(1):122-135.
-
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. J Med Econ. 2024 Jan-Dec; 27(1):109-125.